EFFECTS OF MINERAL CONTENT OF DRINKING WATER ON THE PROGRESSION OF EXPERIMENTAL UREMIA IN RATS

THE AIM of the work was to investigate the content of calcium and magnesium in drinking water on the development of experimental chronic renal failure (CRF) in rats. MATERIALS AND METHODS. Male Wistar rats were subjected to 5/6 nephrectomy (NE). In two weeks after NE the rats were divided into 2 groups. Group 1 received standard Petersburg waterpipe water (8 mg/ l Ca2+ and 3 mg/l Mg2+). Group 2 received water rich in calcium and magnesium (120 mg/l Ca2+ and 45 mg/l Mg2+). Shamoperated rats were taken as control (group 3 received standard Petersburg waterpipe water; group 4 water rich in Ca2+ and Mg 2+). RESULTS. Six weeks later the uremic rats were compared with shamoperated animals. The uremic rats had higher levels of urea and phosphorus in blood serum. However, the content of total calcium was lower in group 1 as compared with group 2. Arterial pressure was considerably higher in group 1 than in groups 2. 3 and 4. Myocardium hypertrophy was noted in less degree in the animals of group 2 than in the rats of group 1. CONCLUSION. We consider that correction of the mineral content of drinking water can slow down the development of arterial hypertension and cardiiovascular disorders in rats with experimental CRF.

1. Kanno Y, Okada H, Takenaka T et al. Influence of the timing of initiating antihypertensive therapy in hypertensive rats with renal failure. Clin Exp Hypertens (New York) 2000; 22 (5): 521529.

2. Шутов АМ, Кондратьева НИ, Ивашкина ТН и др. Диастолическая дисфункция и клинические проявления сердечной недостаточности у больных с додиализной хронической почечной недостаточностью. Нефрология 2001; 5 (4): 3034

3. Leskinen I, Salenius J P, Lehtimaki T et al. The prevalence of peripheral arterial disease and medial arterial calcification in patients with chronic renal failure: requirements for diagnostics. Am J Kidney Dis 2002; 40 (3): 427479

4. Cannela G, Messa P. Pathogenesis and treatment of secondary hyperparathyroidism in chronic renal disease. Int J Artificial Organs 1999; 22 (1): 17

5. Hsu CH. Historical perspective on management of calcium and phosphorus metabolism in chronic renal failure. Am J Kidney Dis 2001; 37 (1): 195201

6. Kamijo T, Gonzalez JM, Jost LJ et al. Renal abnormality of calcium handling in spontaneously hypertensive rats. Kidney Int 1996; [Suppl 55]: S 166168

7. Wu X, Ackermann U, Sonnenberg H. Hypertension development in Dahl Sand R rats on high saltlow potassium diet: calcium, magnesium and sympathetic nervous system. Clin Exp Hypertens 1998; 20 (7): 795815.

8. Inaba M, Okuno S, Imanishi J et al. Magnesium deficiency enhances secretion of parathyroid hormone in normal and 5/6 nephrectomized uremic rats. J Endocrinol Invest 1992; 15 (9) [Suppl 6]: 135142

9. Martinez I, Saracho R, Montenegro J, Liach F. The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis 1997; 29 (4): 496502

10. Иванова ГТ. Особенности кальциевого и магниевого баланса и питьевого поведения крыс, получающих воду с малым и нормальным содержанием кальция и магния. Нефрология 2001; 5 (3): 101102.

11. Шутов АМ, Куликова ЕС, Кондратьева НИ и др. Гипертрофия левого желудочка у больных в додиализном периоде хронической почечной недостаточности, не связанной с сахарным диабетом. Нефрология 2001; 5 (5): 4953

12. Mall G, Huther W, Schneider J et al. Diffuse intramyocardiocytic fibrosis in uremic patients. Nephrol Dial Transplant 1990; 5: 3944

13. Amann K, Ritz E, Wiest G et al. The role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol 1994; 4: 1814 1819

14. Schmieder RE, Schloich MP, Klingbeil AU, Martus P. Update on reversal of left ventricular hyperthrophy in essential hypertension ( a metaanalysis of all randomized doubleblind studied until December 1996). Nephrol Dial Transplant 1998; 13: 564569

15. Kohzuki M, Kamimoto M, Wu XM et al. Renal protective effects of chronic exercise and antihypertensive therapy in hypertensive rats with chronic renal failure. J Hypertens 2001; 19 (10): 18771882

16. Mackenzie HS, Brenner BM. Current strategies for retarding progression of renal disease. Am J Kidney Dis 1998; 31 (1): 161170

17. Foley RN, Parfrey PS. Cardiac disease in chronic uremia: clinical outcome and risk factors. Adv Renal Replace Ther 1997; 4: 234248

18. Levey AS, Eknoyan G. Cardiovascular disease in chronic renal disease. Nephrol Dial Transplant 1999; 14: 828833

19. Schroder H, Schmelz E, Marrugat J. Relationship between diet and blood pressure in a representative mediterranean population. Eur J Nutrition 2002; 41(4): 161167

20. Lim U, Cassano PA. Homocysteine and blood pressure in the Third National Health Nutrition Examination Survey,1988 1994. Am J Epidemiol 2002; 156 (12): 105113

21. Барабанова ВВ, Береснева ОН. Является ли паратиреоидный гормон основным повреждающим фактором сосудов печени при экспериментальной почечной недостаточности. Нефрология 1998; 2 (1): 99104

22. Smogorzewski M. PTH, chronic renal failure and myocardium. Miner Electrolyte Metab 1995; 21 (13): 5562

23. Karkkainen MU, LambergAllardt CJ, Ahonen S, Valimaki M. Does it make a difference how and when you take your calcium? The acute effects of calcium on calcium and bone metabolism. Am J Clin Nutrition 2001; 74 (3): 335342